Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system

Ocular Surface

Volumn 4, Issue 4, 2006, Pages 178-187

  Nesburn, Anthony B ^a   Bettahi, Ilham ^a   Zhang, Xiuli ^a   Zhu, Xiaoming ^a   Chamberlain, Winston ^a   Afifi, Rasha E ^a   Wechsler, Steven L ^a   Benmohamed, Lbachir ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Conjunctiva associated lymphoid tissue (CALT); Epitope; Eye associated lymphoid tissue (EALT); Herpes virus; Immune response; Lipopeptide; Mucosa associated lymphoid tissue (MALT); Mucosal immune system; Ocular mucosal immune system (OMIS); Vaccine

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; HERPES SIMPLEX VACCINE; LIPOPEPTIDE VACCINE; PEPTIDE VACCINE; SUBUNIT VACCINE;

ADJUVANT THERAPY; BLINDNESS; CELLULAR IMMUNITY; CONJUNCTIVA EPITHELIUM; CORNEA EPITHELIUM; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; HERPES SIMPLEX VIRUS 1; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; INFECTION CONTROL; KERATITIS; LACRIMAL GLAND; LYMPH FOLLICLE; MUCOSAL IMMUNITY; NONHUMAN; REVIEW; TEAR FILM; ANIMAL; EYE DISEASE; IMMUNOLOGY; METHODOLOGY; TOPICAL DRUG ADMINISTRATION; VACCINATION;

ADMINISTRATION, TOPICAL; ANIMALS; EYE DISEASES; HUMANS; IMMUNITY, MUCOSAL; VACCINATION; VACCINES, SUBUNIT;

EID: 34447293406     PISSN: 15420124     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-0124(12)70164-7     Document Type: Article

References (79)

1. Liesegang TJ, Melton LJ 3rd, Daly PJ, Ilstrup DM. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol 1989;107:1155-9
2. Zhang X, Issagholian A, Berg EA, et al. 2005. Th-cytotoxic T-lymphocyte chimeric epitopes extended by N(varepsilon)-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tcl responses and protect against ocular infection. J Virol 2005;79:15289-301
3. Nesburn A, Ramos T, Zhu X, et al. Local and systemic B-cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant. Vaccine 2005;23:873-83
4. Carr DJ, Harle P, Gebhardt BM. The immune response to ocular herpes simplex virus type 1 infection. Exp Biol Med (Maywood) 2001;226:353-66
5. Nesburn AB, Burke RL, Ghiasi H, et al. A therapeutic vaccine that reduces recurrent herpes simplex virus type 1 corneal disease. Invest Ophthalmol Vis Sci 1998;39:1163-70
6. Nesburn AB, Slanina S, Burke E, et al. Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits. J Virol 1998;72:7715-21
7. Nesburn AB, Burke RL, Ghiasi H, et al. Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits. Virology 1998;252:200-9
8. Steinglass R, Boyd D, Grabowsky M, et al. Safety, effectiveness and case of use of a non-reusable syringe in a developing country immunization programme. Bull World Health Organ 1995;73:57-63
9. BenMohamed L, Belkaid Y, Loing E, et. al. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur J Immunol 2002;32:2274-81
10. BenMohamed L, Krishnan R, Auge C, et al. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 2002;106:113-21
11. BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines - yesterday, today, and tomorrow. Lancet Infect Dis 2002;2:425-31
12. Toka FN, Pack CD, Rouse BT. Molecular adjuvants for mucosal immunity. Immunol Rev 2004;199:100-12
13. Zhao X, Deak E, Soderberg K, et al. Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2. J Exp Med 2003;197:153-62
14. Mohamadzadeh M, Berard F, Essert G, et al. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med 2001;194:1013-20
15. Pope M, Frankel S, Steinman R, et al. Cutaneous dendritic cells promote replication of immunodeficiency viruses. Adv Exp Med Biol 1997;417:395-9
16. Bergmeier LA, Wang Y, Lehner T. The role of immunity in protection from mucosal SIV infection in macaques. Oral Dis 2002;8 Suppl 2:63-8
17. Decroix N, Hocini H, Quart CP, et al. Induction in mucosa of IgG and IgA antibodies against parenterally administered soluble immunogens. Scand J Immunol 2001;53:401-9
18. Hilbert DM, Anderson AO, Holmes KL, Rudikoff S. Long-term lymphoid reconstitution of SCID mice suggests self-renewing B and T cell populations in peripheral and mucosal tissues. Transplantation 1994;58:466-75
19. Belyakov IM, Derby MA, Ahlers JD, et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Acad Sci U S A 1998; 95:1709-14
20. Lehner T, Bergmeier L, Wang Y, et al. A rational basis for mucosal vaccination against HIV infection. Immunol Rev 1999; 170:183-96
21. Lehner T, Mitchell E, Bergmeier L, et al. The role of gammadelta T cells in generating antiviral factors and beta-chemokines in protection against mucosal simian immunodeficiency virus infection. Eur J Immunol 2000;30:2245-56
22. Lehner T, Bergmeier LA, Wang Y, et al. Heat shock proteins generate beta-chemokines which function as innate adjuvants enhancing adaptive immunity. Eur J Immunol 2000;30:594-603
23. Moriuchi M, Moriuchi H, Williams R, Straus SE. Herpes simplex virus infection induces replication of human immunodeficiency virus type 1. Virology 2000;278:534-40
24. Boyaka PN, Tafaro A, Fischer R, et al. Therapeutic manipulation of the immune system: Enhancement of innate and adaptive mucosal immunity. Curr Pharm Des 2003;9:1965-72
25. Shacklett BL, Yang O, Hausner MA, et al. Optimization of methods to assess human mucosal T-cell responses to HIV infection. J Immunol Methods 2003;279:17-31
26. Pamonsinlapatham P, Decroix N, Mihaila-Amrouche L, et al. Induction of a mucosal immune response to the streptococcal M protein by intramuscular administration of a PADRE-ASREAK peptide. Scand J Inummol 2004;59:501-10
27. Richards CM, Case R, Hirst TR, et al. Protection against recurrent ocular herpes simplex virus type 1 disease after therapeutic vaccination of latently infected mice. J Virol 2003;77:6692-9
28. Byun Y, Ohmura M, Fujihashi K, etal. Nasal immunization with E. coli verotoxin 1 (VT1)-B subunit and a nontoxic mutant of cholera toxin elicits serum neutralizing antibodies. Vaccine 2001;19:2061-70
29. Kuklin NA, Daheshia M, Chun S, Rouse BT. Role of mucosal immunity in herpes simplex virus infection. J Immunol 1998;160:5998-6003
30. Olszewska W, Erume J, Ripley J, et al. Immune responses and protection induced by mucosal and systemic immunisation with recombinant measles nucleoprotein in a mouse model of measles virus-induced encephalitis. Arch Virol 2001;146:293-302
31. Gallichan WS, Woolstencroft RN, Guarasci T, et al. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol 2001;166:3451-7
32. Parr EL, Parr MB. Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2. Immunology 1999;98:639-45
33. Knop N, Knop E. Ultrastructural anatomy of CALT follicles in the rabbit reveals characteristics of M-cells, germinal centres and high endothelial venules. J Anat 2005;207:409-26
34. Knop E, Knop N. The role of eye-associated lymphoid tissue in corneal immune protection. J Anat 2005;206:271-85
35. Knop E, Knop N. [Eye-associated lymphoid tissue (EALT) is continuously spread throughout the ocular surface from the lacrimal gland to the lacrimal drainage systeml. Ophthalmologe 2003;100:929-42. German
36. Knop E, Knop N, Brewitt H. [Dry eye disease as a complex dysregulation of the functional anatomy of the ocular surface. New concepts for understanding dry eye disease]. Ophthalmologe 2003;100:917-28. German
37. Kuper CF, Koornstra PJ, Hameleers DM, et al. The role of nasopharyngeal lymphoid tissue. Immunol Today 1992;13:219-24
38. Bouchard CS, Lasky JB, Cundiff JE, Smith BS. Ocular surface upregulation of intercellular adhesive molecule-1 (ICAM-1) by local interferon-gamma (IFN-gamma) in the rat. Curr Eye Res 1996;15:203-8
39. Hannah P, Liu Y, Zhang Q, Dana MR. The corneal stroma is endowed with a significant number of resident dendritic cells. Invest Ophthalmol Vis Sci 2003;44:581-9
40. Ksander BR, Hendricks RL. Cell-mediated immune tolerance to HSV-1 antigens associated with reduced susceptibility to HSV-1 corneal lesions. Invest Ophthalmol Vis Sci 1987;28:1986-93
41. Martin TM, Smith JR, Rosenbaum JT. Anterior uveitis:cUrrent concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Opin Rheumatol 2002;14:337-41
42. Allansmith MR, Cornell-Bell AH, Baird RS, et al. Conjunctival basophil hypersensitivity in the guinea pig. J Allergy Clin Imnumol 1986;78:919-27
43. Ridley Lathers DM, Gill RF, Montgomery PC. Inductive pathways leading to rat tear IgA antibody responses. Invest Ophthalmol Vis Sci 1998;39:1005-11
44. Montgomery PC, Rockey JH, Majumdar AS, et al. Parameters influencing the expression of IgA antibodies in tears. Invest Ophthalmol Vis Sci 1984;25:369-73
45. Saitoh-Inagawa W, Hiroi T, Yanagita M, et al. Unique characteristics of lacrimal glands as a part of mucosal immune network: High frequency of IgA-committed B-1 cells and NK1.1 + alphabeta T cells. Invest Ophthalmol Vis Sci 2000;41:138-44
46. Rouse BT, Suvas S. Regulatory cells and infectious agents: Detentes cordiale and contraire. J Immunol 2004;173:2211-5
47. Mircheff AK, Gierow JP, Yang T, et al. Sjogren's autoimmunity: How perturbation of recognition in endomembrane traffic may provoke pathological recognition at the cell surface. J Mol Recognit 1998;11:40-8
48. Koelle DM, Reymond SN, Chen H, et al. Tegument-specific, virus-reactive CD4 T cells localize to the cornea in herpes simplex virus interstitial keratitis in humans. J Virol 2000;74:10930-8
49. Metcalf JF, Chatterjee S, Koga J, Whitley RJ. Protection against herpetie ocular disease by immunotherapy with monoclonal antibodies to herpes simplex virus glycoproteins. Intervirology 1988;29:39-49
50. Zhu Z, Stevenson D, Schechter JE, et al. Lacrimal histopathology and ocular surface disease in a rabbit model of automimune dacryoadenitis. Cornea 2003:22:25-32
51. Wood RL, Trousdale MD, Stevenson D, et al. Adenovirus infection of the cornea causes histopathologic changes in the lacrimal gland. Curr Eye Res 1997;16:459-66
52. Willey DE, Maguen E, Pinhas S, et al. Antibody response following implantation of xenrogenic lenticules. Cornea 1984;3:33-6
53. Openshaw H, McNeill JI, Lin XH, et al. Herpes simplex virus DNA in nonnal corneas: Persistence without viral shedding from ganglia. J Med Virol 1995;6:75-80
54. Hamrah P, Huq SO, Liu Y, et al. Corneal immunity is mediated by heterogeneous population of antigen-presenting cells. J Leukoc Biol 2003;74:172-8
55. Liu Y, Hamrah P, Zhang Q. et al. Draining lymph nodes of corneal transplant hosts exhibit evidence for donor major histocompatibility complex (MHC) class II-positive dendritic cells derived from MHC class II-negative grafts. J Exp Med 2002;195:259-68
56. Qian Y, Hamrah P, Boisgerault F, et al. Mechanisms of immunotherapeutic intervention by anti-CD154 (CD40L) antibody in high-risk corneal transplantation. J Interferon Cytokine Res 2002;22:1217-25
57. Dana MR, Qian Y, Hamrah P. Twenty-five-year panorama of corneal immunology: Emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection. Cornea 2000;19:625-43
58. Daheshia M, Kuklin N, Kanangat S, et al. Suppression of ongoing ocular inflammatory disease by topical administration of plasmid DNA encoding IL-10. J Immunol 1997;159:1945-52
59. Trousdale MD, Zhu Z, Stevenson D, et al. Expression of TNF inhibitor gene in the lacrimal gland promotes recovery of tear production and tear stability and reduced immunopathology in rabbits with induced autoimmune dacryoadenitis.J Autoimmune Dis 2005;2:6
60. Holmgren J, Czerkinsky C, Eriksson K, Mharandi A. Mucosal immunisation and adjuvants: A brief overview of recent advances and challenges. Vaccine 2003;21 Suppl 2:S89-95
61. McCluskie MJ, Weeratna RD, Krieg AM, Davis HL. CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine 2000;19:950-7
62. Vollmer J, Weeratna R, Payette P, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004;34:251-62
63. Gierynska M, Kumaraguru U, Eo SK, et al. Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes. J Virol 2002;76:6568-76
64. Kumar S, Jones TR, Oakley MS, et al. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect Immun 2004;72:949-57
65. Jakob T, Walker PS, Krieg AM, et al. Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: Implications for the augmentation of Th1 responses. Int Arch Allergy Immunol 1999;118:457-61
66. Gramzinski RA, Doolan DL, Sedegah M, et al. Interleukin-12-and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun 2001;69:1643-9
67. McCluskie MJ, Davis HL. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 1998;161:4463-6
68. Yamamoto M, Briles DE, Yamamoto S, et al. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J Immunol 1998;161:4115-21
69. Marinaro M, Boyaka PN, Jackson RJ, et al. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin. J Immunol 1999;162:114-21
70. Singh M, Briones M, O'Hagan DT. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J Control Release 2001;70:267-76
71. Weeratna RD, Brazolot Millan CL, McCluskie MJ, Davis HL. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol Med Microbiol 2001;32:65-71
72. Lenert P, Rasmussen W, Ashman RF, Ballas ZK. Structural characterization of the inhibitory DNA motif for the type A (D)-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cells. DNA Cell Biol 2003;22:621-31
73. Ikeda RK, Miller M, Nayar J, et al. Accumulation of peribronchial mast cells in a mouse model of ovalbumin allergen induced chronic airway inflammation:mOdulation by immunostimulatory DNA sequences. J Immunol 2003;171:4860-7
74. Mutwiri G, Pontarollo R, Babiuk S, et al. Biological activity of immunostimulatory CpG DNA motifs in domestic animals. Vet Immunol Immunopathol 2003;91:89-103
75. Flo TH, Ryan L, Latz E, et al. Involvement of toll-like receptor (TLR) 2 and TLR4 in cell activation by mannuronic acid polymers. J Biol Chem 2002;277:35489-95
76. Tsuji S, Matsumoto M, Takeuchi O, et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin:iNvolvement of toll-like receptors. Infect Immun 2000;68:6883-90
77. Bauer S, Kirschning CJ, Hacker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 2001;98:9237-42
78. Kirschning CJ, Bauer S. Toll-like receptors: Cellular signal transducers for exogenous molecular patterns causing immune responses. Int J Med Microbiol 2001;291:251-60
79. Edwards AD, Diebold SS, Slack EM, et al. Toll-like receptor expression in murine DC subsets:lAck of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol 2003;33:827-33